Drugs / busulifan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03882203 | Aug 2018 → Aug 2021 | refractory hematologic cancer | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | busulifan | “Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan” NCT03882203 ↗ |